Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buprenorphine transdermal - Grunenthal

X
Drug Profile

Buprenorphine transdermal - Grunenthal

Alternative Names: Transdermal buprenorphine - Grunenthal; Transtec; Transtec twice-weekly

Latest Information Update: 13 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grunenthal
  • Developer Grunenthal; Napp Pharmaceutical Group; Norpharma; Taiwan Mundipharma Pharmaceuticals
  • Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Pain

Most Recent Events

  • 01 Jun 2017 Launched for Cancer pain in Taiwan (Transdermal) (NCT04315831)
  • 01 Apr 2014 Buprenorphine licensed to Taiwan Mundipharma in Asia, Middle East and Africa
  • 31 May 2007 Launched for Pain in Hungary (Transdermal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top